Mark Wallace, MD, Director of the Center for Clinical Research (CCR) at ACTRI, recently received National Institute of Health (NIH) funding for his Specialized Clinical Center at UCSD, called the California Clinical and Translational Research Consortium. The Consortium includes the UCSD ACTRI as its hub, with UC San Francisco, UC Irvine and UC Davis as collaborative locations and will operate as a clinical trials network. The team will design and execute innovative trials of non-addictive pain therapies to reduce the burden of pain and risk of addiction to pain management medications.
The consortium and the ACTRI will engage the newly developed Early Phase Pain Investigation Clinical Network (EPPIC-Net) led by the National Institute of Neurological Disorders and Stroke (NINDS). The NIH is committed to the Helping to End Addiction Long-term HEAL) Initiative launched in 2018, and will utilize EPPIC-Net as the new cornerstone to advance infrastructure and research that solves the national opioid public health crisis. Specifically, EPPIC-Net will focus on proof of concept testing and validation of phenotyping and biomarker studies for patients with pain conditions, in addition to Phase 2 clinical trials that will test novel therapeutics.
With the CCR selected as one of 10 specialized clinical centers, Dr. Wallace will actively engage study participants and provide scientific leadership and administrative oversight to its collaborating campuses. Working with the national Clinical Coordinating Center (CCC) and one Data Coordinating Center (DCC), EPPIC-Net will improve the quality and speed of research designed to help patients with chronic and acute pain.